Europe Cancer Cachexia Market - 2024-2031
Europe Cancer Cachexia Market reached US$ 618.75 million in 2022 and is expected to reach US$ 897.58 million by 2031, growing with a CAGR of 4.80% during the forecast period 2026-2031.
The Europe Cancer Cachexia Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Europe Cancer Cachexia Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Therapeutics
Both primary and secondary data sources have been used in the global Europe Cancer Cachexia Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Europe Cancer Cachexia Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Europe Cancer Cachexia Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Therapeutics
- Corticosteroids *
- Cannabinoids (Dronabinol)
- Anabolic Steroids
- Cytokine Inhibitors
- Others
- Appetite Stimulator*
- Weight Loss Stabilizers
- Others
- Hospital Stores*
- Retail Pharmacy Stores
- Online Pharmacy
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Europe Cancer Cachexia Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. MARKET METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing incidences of cancer cachexia
4.1.1.2. Government fundings
4.1.1.3. Increasing clinical trials and research activities in Europe
4.1.2. Restraints:
4.1.2.1. High cost of treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
5.4. Pipeline Analysis
5.5. Pricing Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. BY THERAPEUTICS
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
7.1.2. Market Attractiveness Index, By Therapeutics
7.2. Corticosteroids *
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
7.3. Cannabinoids (Dronabinol)
7.4. Anabolic Steroids
7.5. Cytokine Inhibitors
7.6. Others
8. BY MECHANISM
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mechanism
8.1.2. Market Attractiveness Index, By Mechanism
8.2. Appetite Stimulator*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
8.3. Weight Loss Stabilizers
8.4. Others
9. BY DISTRIBUTION CHANNEL
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Stores*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
9.3. Retail Pharmacy Stores
9.4. Online Pharmacy
10. BY COUNTRY
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Country
10.1.2. Market Attractiveness Index, By Country
10.2. Germany
10.2.1. Introduction
10.2.2. Key Country-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mechanism
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3. The U.K.
10.3.1. Introduction
10.3.2. Key Country-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mechanism
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4. France
10.4.1. Introduction
10.4.2. Key Country-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mechanism
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5. Italy
10.5.1. Introduction
10.5.2. Key Country-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mechanism
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.6. Spain
10.6.1. Introduction
10.6.2. Key Country-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mechanism
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.7. Rest of Europe
10.7.1. Introduction
10.7.2. Key Country-Specific Dynamics
10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mechanism
10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11. COMPETITIVE LANDSCAPE
11.1. Key Developments and Strategies
11.2. Merger and Acquisitions
11.3. Product Benchmarking
12. COMPANY PROFILES
12.1. Actimed Therapeutics Ltd.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Aphios Corporation
12.3. Bristol-Myers Squibb Company
12.4. Pfizer Inc.
12.5. Helsinn Group
12.6. Merck & Co. Inc.
12.7. Fresenius Kabi AG
12.8. NGM Biopharmaceuticals
12.9. Aveo Oncology
12.10. AAVogen Inc.(*LIST NOT EXHAUSTIVE)
13. DATAM INTELLIGENCE
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing incidences of cancer cachexia
4.1.1.2. Government fundings
4.1.1.3. Increasing clinical trials and research activities in Europe
4.1.2. Restraints:
4.1.2.1. High cost of treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
5.4. Pipeline Analysis
5.5. Pricing Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. BY THERAPEUTICS
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
7.1.2. Market Attractiveness Index, By Therapeutics
7.2. Corticosteroids *
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
7.3. Cannabinoids (Dronabinol)
7.4. Anabolic Steroids
7.5. Cytokine Inhibitors
7.6. Others
8. BY MECHANISM
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mechanism
8.1.2. Market Attractiveness Index, By Mechanism
8.2. Appetite Stimulator*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
8.3. Weight Loss Stabilizers
8.4. Others
9. BY DISTRIBUTION CHANNEL
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Stores*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
9.3. Retail Pharmacy Stores
9.4. Online Pharmacy
10. BY COUNTRY
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Country
10.1.2. Market Attractiveness Index, By Country
10.2. Germany
10.2.1. Introduction
10.2.2. Key Country-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mechanism
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3. The U.K.
10.3.1. Introduction
10.3.2. Key Country-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mechanism
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4. France
10.4.1. Introduction
10.4.2. Key Country-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mechanism
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5. Italy
10.5.1. Introduction
10.5.2. Key Country-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mechanism
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.6. Spain
10.6.1. Introduction
10.6.2. Key Country-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mechanism
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.7. Rest of Europe
10.7.1. Introduction
10.7.2. Key Country-Specific Dynamics
10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mechanism
10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11. COMPETITIVE LANDSCAPE
11.1. Key Developments and Strategies
11.2. Merger and Acquisitions
11.3. Product Benchmarking
12. COMPANY PROFILES
12.1. Actimed Therapeutics Ltd.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Aphios Corporation
12.3. Bristol-Myers Squibb Company
12.4. Pfizer Inc.
12.5. Helsinn Group
12.6. Merck & Co. Inc.
12.7. Fresenius Kabi AG
12.8. NGM Biopharmaceuticals
12.9. Aveo Oncology
12.10. AAVogen Inc.(*LIST NOT EXHAUSTIVE)
13. DATAM INTELLIGENCE
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us
